Jae Park, MD

Articles

CAR T Therapy for Relapsed/Refractory B-Cell ALL: Selecting Appropriate Patients

February 1st 2022

Implications of the ZUMA-3 clinical trial of anti-CD19 CAR T-cell therapy for adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Relapsed Refractory B-Cell ALL: Patient Prognosis

Elias Jabbour, MD;Jae Park, MD

January 25th 2022

Background information regarding the manifestation and prognosis of relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr. Park on Selecting Among Available CAR T-Cell Therapies in MCL

Jae Park, MD

August 5th 2021

Jae Park, MD, discusses the factors to consider when selecting among the available CAR T-cell therapies for the treatment of patients with mantle cell lymphoma.

Jae H. Park, MD, of Memorial Sloan Kettering Cancer Center

Dr. Park on Emerging CAR T-Cell Therapies in Hematologic Malignancies

Jae Park, MD;Jae H. Park, MD

August 3rd 2021

Jae H. Park, MD, discusses emerging CAR T-cell therapies in hematologic malignancies.

Dr. Park on the Benefits of Off-the-Shelf CAR T-Cell Therapy in ALL

Jae Park, MD

August 10th 2020

Jae Park, MD, discusses the benefits of off-the-shelf CAR T-cell therapy in acute lymphoblastic leukemia.

$Dr. Park on Considerations of CAR T-Cell Therapy in Relapsed/Refractory ALL$

Dr. Park on Considerations of CAR T-Cell Therapy in Relapsed/Refractory ALL

Jae Park, MD

August 7th 2020

Jae Park, MD, discusses considerations for CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia.

Dr. Park on Ongoing Research Efforts With CAR T-Cell Therapies in ALL

Jae Park, MD

April 2nd 2020

Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discusses the use of CAR T-cell therapies in patients with acute lymphocytic leukemia.

Dr. Park on CD19-Directed CAR T-Cell Therapy in Patients With ALL

Jae Park, MD

April 6th 2018

Jae Park, MD, hematologist oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential of CD19-targeted chimeric antigen receptor (CAR) T-cell therapy in adult patients with acute lymphoblastic leukemia (ALL).

Dr. Jae Park on Impact of Disease Burden on CAR T-Cells in Relapsed B-ALL

Jae Park, MD

June 10th 2016

Dr. Park on Using CD19-Targeted CAR T Cells as Treatment for ALL

Jae Park, MD

December 16th 2014

Jae H. Park, MD, attending physician, Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses a trial presented at the 2014 ASH Annual Meeting that explored CD19-targeted T cells as treatment for patients with relapsed, refractory B- cell ALL.